NasdaqGM:FATE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Fate Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FATE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

FATE

-0.9%

US Biotechs

2.5%

US Market


1 Year Return

67.1%

FATE

24.5%

US Biotechs

8.4%

US Market

Return vs Industry: FATE exceeded the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: FATE exceeded the US Market which returned 7.1% over the past year.


Shareholder returns

FATEIndustryMarket
7 Day-8.5%-0.9%2.5%
30 Day11.0%3.2%5.1%
90 Day10.3%13.6%2.0%
1 Year67.1%67.1%25.7%24.5%10.9%8.4%
3 Year807.6%807.6%32.2%27.8%30.5%21.9%
5 Year411.4%411.4%-3.4%-9.2%56.9%39.2%

Price Volatility Vs. Market

How volatile is Fate Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fate Therapeutics undervalued compared to its fair value and its price relative to the market?

11.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: FATE ($33.09) is trading above our estimate of fair value ($3.22)

Significantly Below Fair Value: FATE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: FATE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FATE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FATE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FATE is overvalued based on its PB Ratio (11.5x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Fate Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

9.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FATE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FATE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FATE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FATE's revenue (73.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: FATE's revenue (73.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FATE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Fate Therapeutics performed over the past 5 years?

-29.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FATE is currently unprofitable.

Growing Profit Margin: FATE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FATE is unprofitable, and losses have increased over the past 5 years at a rate of -29.5% per year.

Accelerating Growth: Unable to compare FATE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FATE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: FATE has a negative Return on Equity (-51.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fate Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FATE's short term assets ($208.2M) exceed its short term liabilities ($24.9M).

Long Term Liabilities: FATE's short term assets ($208.2M) exceed its long term liabilities ($77.7M).


Debt to Equity History and Analysis

Debt Level: FATE is debt free.

Reducing Debt: FATE has no debt compared to 5 years ago when its debt to equity ratio was 89.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FATE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FATE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 27.1% each year.


Next Steps

Dividend

What is Fate Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FATE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FATE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FATE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FATE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FATE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

J. Wolchko (49yo)

4.42yrs

Tenure

US$10,720,955

Compensation

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD10.72M) is above average for companies of similar size in the US market ($USD5.91M).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
J. Wolchko
Founder4.42yrsUS$10.72m0.13% $3.3m
Daniel Shoemaker
Chief Scientific Officer5yrsUS$2.82m0.11% $2.8m
Cindy Tahl
General Counsel & Corporate Secretary4.58yrsUS$2.82m0.057% $1.4m
Bahram Valamehr
Chief Development Officer2.33yrsUS$2.82m0.041% $1.0m
Wen Wang
Senior Vice President of Technical Operations1.58yrsno datano data
Jim Beitel
Senior Vice President of Corporate Development2.67yrsno datano data
Sarah Cooley
Senior Vice President of Clinical Translation1.17yrsno datano data
Yu-Waye Chu
Senior Vice President of Clinical Development0.33yrno datano data

2.5yrs

Average Tenure

47.5yo

Average Age

Experienced Management: FATE's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
J. Wolchko
Founder4.42yrsUS$10.72m0.13% $3.3m
William Rastetter
Independent Chairman8.5yrsUS$277.14k0.78% $19.5m
John Mendlein
Independent Vice Chairman of the Board8.5yrsUS$245.98k0.20% $5.1m
Robert Langer
Member of Scientific Advisory Boardno datano datano data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Stuart Orkin
Member of Scientific Advisory Board10yrsno datano data
Sui Huang
Member of Scientific Advisory Board10yrsno datano data
Timothy Coughlin
Independent Director6.75yrsUS$250.95k0.073% $1.8m
Sean Morrison
Member of Scientific Advisory Board10yrsno datano data
Mark Krasnow
Member of Scientific Advisory Board10yrsno datano data

9.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: FATE's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.


Top Shareholders

Company Information

Fate Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fate Therapeutics, Inc.
  • Ticker: FATE
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.503b
  • Shares outstanding: 77.69m
  • Website: https://www.fatetherapeutics.com

Number of Employees


Location

  • Fate Therapeutics, Inc.
  • 3535 General Atomics Court
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FATENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2013
F6TDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company’s NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 04:36
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.